Market Pathways editors Steve Levin and David Filmore discuss important  medtech regulatory and policy developments they are looking for in 2022.  In this episode, they delve into the US picture, including what to  expect from Congress, FDA, and CMS. Check out the second part of the  conversation, where they discuss the environments in Europe and Asia, in  the next episode.   

Read more about the topics discussed in these Market Pathways articles:  

Pathways’ Picks for 2022: 7 Medtech Policy Issues to Watch

Q&A: AdvaMed’s Scott Whitaker on Partnering, Advocacy, and the  Medtech Policy Year Ahead

Device User Fee Talks Stalled as a Deadline Approaches